Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

Sun, Zhengwu; Lan, Xiaoyan; Xu, Shizhao; Li, Shen; Xi, Yalin

doi:10.1186/s12885-020-6674-1

Table 1 Characteristics of the studies included in the network meta-analysis

From: Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

Study ID	Treatment 1								Treatment 2								Style
	n	Age (years)		Intervention	Receptor status		Prior therapy		n	Age (years)		Intervention	Receptor status		Prior therapy
	n	Median	Range	Intervention	ER+/PR+	TN	Chemo	Hormono	n	Median	Range	Intervention	ER+/PR+	TN	Chemo	Hormono
Norikazu Masuda 2017 [7]	24	53	32–78	Bev + Tax	22	2	9	15	30	60	28–71	Tax	24	6	13	19	RCT
David Miles 2017 [8]	239	55	28–85	Bev + Tax	200	39	116	92	242	56	28–77	Tax	203	39	118	105	RCT
Christoph Rochlitz 2016 [19]	71	64	30–82	Bev + Tax	61	10	38	NA	68	62	29–81	Bev + Cap+Cyc	52	15	37	NA	RCT
Christoph Zielinski 2016 [12]	266	NA	NA	Bev + Tax	205	60	142	50	265	NA	NA	Bev + Cap	201	64	143	43	RCT
A. Welt 2016 [16]	295	63	34–88	Bev + Cap+Vin	233	61	195	169	297	61	29–85	Bev + Cap	236	61	193	171	RCT
O. Trédan 2016 [20]	58	56	35–77	Bev + Exm	57	1	35	33	59	55	35–86	Bev + Tax	59	0	38	39	RCT
Denise A. Yardley 2015 [17]	56	61	30–77	Bev + Tax+Exr	44	12	34	34	57	57	25–79	Bev + Tax	45	12	31	37	RCT
Veronique Dieras 2015 [18]	56	57	32–75	Bev + Tax+Tre	45	9	10	NA	58	52	31–74	Bev + Tax	45	12	11	NA	RCT
Hans-Joachim Luck 2015 [15]	111	57	31–78	Bev + Tax+Cap	111	0	NA	NA	116	57	31–80	Bev + Tax	116	0	NA	NA	RCT
S.W. Lam 2014 [13]	156	56	32–76	Bev + Tax+Cap	133	23	90	82	156	56	34–74	Bev + Tax	132	24	89	76	RCT
Joseph Gligorov 2014 [14]	91	49	24–80	Bev + Tax+Cap	66	25	NA	NA	94	54	24–77	Bev + Tax	73	21	NA	NA	RCT
Istvan Lang 2013 [11]	279	59	48–65	Bev + Cap	212	67	176	171	285	59	49–64	Bev + Tax	222	63	180	175	RCT
Adam M. Brufsky 2011 [21]	201	56	28–86	Bev + Tax	145	47	NA	NA	103	56	35–84	Tax	77	20	NA	NA	RCT
Adam M. Brufsky 2011 [21]	97	57	31–78	Bev + Cap	74	18	NA	NA	47	50	23–90	Cap	36	10	NA	NA	RCT
Miguel Martin 2011 [22]	97	55	44–66	Bev + Tax	78	19	64	64	94	53	43–63	Tax	75	19	62	56	RCT
	91	55	44–66	Mot + Tax	73	18	60	58	94	53	43–63	Tax	75	19	62	56	RCT
	97	55	44–66	Bev + Tax	78	19	64	64	91	55	44–66	Mot + Tax	73	18	60	58	RCT
David W. Miles 2010 [9]	247	55	27–76	Bev + Tax	187	60	167	120	241	55	29–83	Tax	189	52	156	135	RCT
Robert Gray 2009 [10]	368	56	29–84	Bev + Tax	223	120	244	NA	354	55	27–85	Tax	223	99	231	NA	RCT

Bev bevacizumab, Cap capecitabine, Vin vinorelbine, Cyc cyclophosphamide, Exm exemestane, Exr everolimus, Tre trebananib, Mot motesanib, RCTs randomized controlled trials, NA not applicable, n number of patients, Receptor Status hormone receptor status, ER+/PR+ estrogen receptor (ER) and/or progesterone receptor (PR) positive, TN triple negative, Chemo prior chemotherapy, Hormono prior hormonal therapy

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us